Inhibiting transforming growth factor-β in pancreatic cancer to encourage vascular normalisation and improve therapeutic response
Year: 2026
Type: dissertation
Abstract: Pancreatic ductal adenocarcinoma (PDAC) is the fifth most common cause of cancer death in the UK. The most effective treatment is surgery, followed by adjuvant chemotherapy, however this treatment option is only available to 10-20% of patients, and the standard-of-care chemotherapy, gemcitabine, has a 5-year overall survival rate of 31.4%. The PDAC tumour microenvironment is one of the main contributors to poor treatment response, and it is made up of a dense desmoplastic stroma, caused by cancer-associated fibroblasts, stromal cells that cause fibrosis and produce collagen, contributing to a stiff extracellular matrix. This dense stroma creates a hypoxic environment, with limited and non-functional blood vessels, exhibiting disorganised lining and leaky structures that impedes drug delivery, increases drug resistance and promotes metastasis. TGF-β is an anti-inflammatory cytokine that has many roles in cancer development including angiogenesis, the formation of new blood vessels. Inhibiting TGF-β has previously been used in other cancers to normalise tumour vasculature, reduce the hypoxic environment, enhance immune cell infiltration and improve drug delivery, however this effect has not been investigated in PDAC. This study investigates the effect of inhibiting TGF-β on cells and tumour vasculature in pancreatic cancer. PDAC cell lines were used to determine the effect of a TGF-β receptor inhibitor, LY2109671 on cell viability, with inhibition decreasing viability in a dose-dependent manner. Changes in protein and mRNA expression were investigated with TGF-β increasing expression levels of the latent TGF-β, an effect that was inhibited by LY2109671. Fibroblast, and endothelial cells also demonstrated LY2109671 inhibition of TGF-β induced protein and mRNA expression of TGF-β, COL1A1 and bFGF. Finally, LY2109671 was able to reverse the TGF-β-induced suppression of vessel formation in fibroblast and endothelial co cultures. The results of this study highlight a potential treatment option to be used alongside standard-of-care chemotherapy to improve treatment response in PDAC patients.
Author: Redfearn, Isabella Daisy
Institution: York St John University
Language: English
Subfield: Oncology
Field: Medicine
Domain: Health Sciences
Open Access status: green
OpenAlex ID: W7225280900
